









Markets
/
Stocks
/
nasdaq-acon
/

Aclarion Inc

ACON

3.090USD

-0.190-5.79%

Market hours （ET）Quotes delayed by 15 min

167.02Market Cap

LossP/E TTM



Aclarion Inc

3.090

-0.190-5.79%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aclarion Inc

Currency: USD Updated: 2026-03-27

Key Insights

Aclarion Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 200 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aclarion Inc's Score

Industry at a Glance

Industry Ranking

200 / 391

Overall Ranking

378 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Aclarion Inc Highlights

StrengthsRisks

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Growing

The company is in a growing phase, with the latest annual income totaling USD 75.73K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 75.73K.

Undervalued

The company’s latest PE is -0.22, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 6.78K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

23.000

Target Price

+601.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Aclarion Inc is 6.57, ranking 234 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 18.48K, representing a year-over-year increase of 80.60%, while its net profit experienced a year-over-year increase of 7.26%.

Score

Industry at a Glance

Previous score

6.57

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.73

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Aclarion Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Aclarion Inc is 6.52, ranking 256 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.22, which is -99.33% below the recent high of -0.00 and -654.74% above the recent low of -1.70.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 200/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Aclarion Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 23.00, with a high of 23.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

23.000

Target Price

+601.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Aclarion Inc

ACON

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Aclarion Inc is 1.00, ranking 387 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.56 and the support level at 2.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.019

Buy

RSI(14)

46.059

Neutral

STOCH(KDJ)(9,3,3)

24.416

Sell

ATR(14)

0.225

Low Volatility

CCI(14)

-140.474

Sell

Williams %R

94.690

Oversold

TRIX(12,20)

0.497

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.228

Sell

MA10

3.238

Sell

MA20

3.199

Sell

MA50

3.105

Sell

MA100

4.612

Sell

MA200

6.088

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Aclarion Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 1.59%, representing a quarter-over-quarter increase of 80.79%. The largest institutional shareholder is The Vanguard, holding a total of 6.78K shares, representing 0.30% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

CAPTRUST Financial Advisors

10.00K

The Vanguard Group, Inc.

Star Investors

6.78K

Geode Capital Management, L.L.C.

2.06K

UBS Financial Services, Inc.

-100.00%

Tower Research Capital LLC

581.00

+674.67%

Ness (Brent)

13.00

+333.33%

Thramann (Jeffrey John)

10.00

Neal (David K)

2.00

BofA Global Research (US)

8.00

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aclarion Inc is 1.84, ranking 271 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.